Atrys Health (XMAD:ATRY) ROCE %: -20.16% (As of Dec. 2025)


XMAD:ATRY Atrys Health SA XMAD:ATRY
66 GF Score
Price €2.57
GF Value €3.11
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Atrys Health ROCE %?

Atrys Health XMAD:ATRY -0.97% 66 ROCE % is -20.16% as of Dec. 2025. GuruFocus rates XMAD:ATRY with a GF Score™ of 66/100 and a GF Value™ of €3.11 (Modestly Undervalued). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Atrys Health's annualized ROCE % for the quarter that ended in Dec. 2025 was -20.16%.

Atrys Health  (XMAD:ATRY) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Atrys Health ROCE % Related Terms

Atrys Health ROCE % Historical Data

* Premium members only.

The historical data trend for Atrys Health's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atrys Health ROCE % Chart

Atrys Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.25 -2.24 -0.11 -2.39 -10.81

Atrys Health Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.82 -2.31 -1.20 0.36 -20.16
XMAD:ATRY
66GF Score
Atrys Health SA XMAD:ATRY
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atrys Health ROCE % Calculation

Atrys Health's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-37.178/( ( (584.194 - 99.788) + (494.041 - 290.42) )/ 2 )
=-37.178/( (484.406+203.621)/ 2 )
=-37.178/344.0135
=-10.81 %

Atrys Health's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-67.676/( ( (579.134 - 111.288) + (494.041 - 290.42) )/ 2 )
=-67.676/( ( 467.846 + 203.621 )/ 2 )
=-67.676/335.7335
=-20.16 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -20.16% mean?
Atrys Health (XMAD:ATRY) has a ROCE % of -20.16% as of Dec. 2025.
Is Atrys Health's ROCE % too high?
Atrys Health's current ROCE % is -20.16%. Overall, Atrys Health has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Atrys Health's ROCE % compare to VRTX and REGN?
Atrys Health's ROCE % of -20.16% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Atrys Health's current ROCE % is -20.16%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrys Health stock overvalued right now?
Based on GuruFocus' analysis, Atrys Health (XMAD:ATRY) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.11, compared to a current price of €2.57 — trading 17.5% below its estimated fair value. The current ROCE % is -20.16%. Atrys Health's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Atrys Health (XMAD:ATRY), the current ROCE % is -20.16% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Atrys Health (XMAD:ATRY) Overvalued in 2026?

Based on GuruFocus' analysis, Atrys Health stock appears to be undervalued. The current stock price of €2.57 is trading 17.5% below its estimated GF Value™ of €3.11. GuruFocus considers Atrys Health to be Modestly Undervalued.

Key valuation signals for XMAD:ATRY:

  • ROCE %: -20.16%
  • GF Value™: €3.11 vs. price of €2.57 (17.5% below fair value)
  • GF Score™: 66/100 with 5 warning signs

No single metric tells the full story. See the XMAD:ATRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Atrys Health Business Description

Other Exchanges A2T:Germany
Address Calle Provenca, 392 planta baja, Barcelona, ESP, 08025
Atrys Health SA is a Spain based biomedical company which focuses on developing tools for the diagnosis and treatment of cancer and precancerous conditions. It offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics. The company uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology.
66GF Score

Get the complete analysis for XMAD:ATRY

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.57
Price
€3.11
GF Value